HK1174615A1 - Ghrelin receptor agonist for treatment of dyscrasia - Google Patents
Ghrelin receptor agonist for treatment of dyscrasiaInfo
- Publication number
- HK1174615A1 HK1174615A1 HK13101402.5A HK13101402A HK1174615A1 HK 1174615 A1 HK1174615 A1 HK 1174615A1 HK 13101402 A HK13101402 A HK 13101402A HK 1174615 A1 HK1174615 A1 HK 1174615A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- dyscrasia
- treatment
- receptor agonist
- ghrelin receptor
- ghrelin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010043484 | 2010-02-26 | ||
| PCT/JP2011/054556 WO2011105611A1 (ja) | 2010-02-26 | 2011-02-28 | 悪液質を治療するためのグレリン受容体作動物質 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1174615A1 true HK1174615A1 (en) | 2013-06-14 |
Family
ID=44507004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK13101402.5A HK1174615A1 (en) | 2010-02-26 | 2013-01-31 | Ghrelin receptor agonist for treatment of dyscrasia |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10975070B2 (pt) |
| EP (1) | EP2540721B1 (pt) |
| JP (1) | JPWO2011105611A1 (pt) |
| KR (1) | KR20120131183A (pt) |
| CN (1) | CN102762564B (pt) |
| BR (1) | BR112012020377B1 (pt) |
| CA (1) | CA2789750C (pt) |
| ES (1) | ES2615731T3 (pt) |
| FR (1) | FR23C1048I1 (pt) |
| HK (1) | HK1174615A1 (pt) |
| MX (1) | MX341660B (pt) |
| RU (1) | RU2012141061A (pt) |
| WO (1) | WO2011105611A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3524260T3 (da) * | 2012-09-27 | 2023-10-09 | Elanco Animal Health Incorporated | Farmaceutiske sammensætninger til behandling af manglende appetit |
| TWI629982B (zh) * | 2013-05-28 | 2018-07-21 | 拉夸里亞創藥股份有限公司 | 多晶型形式 |
| TW201625613A (zh) * | 2014-10-31 | 2016-07-16 | 拉夸里亞創藥股份有限公司 | 作為生長激素釋放肽受體激動劑之四氫吡唑並吡啶衍生物 |
| JP6467513B2 (ja) * | 2015-01-28 | 2019-02-13 | アラタナ セラピューティクス、 インコーポレイテッド | 体重増加用化合物の長期使用のための組成物と方法 |
| WO2022065831A1 (ko) * | 2020-09-22 | 2022-03-31 | 경북대학교 산학협력단 | 그렐린 수용체 작용제로서의 트리아졸 화합물의 용도 |
| CN115778960A (zh) * | 2022-08-19 | 2023-03-14 | 广州六顺生物科技有限公司 | 一种杂芳环衍生物在制备治疗或预防恶病质药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4997984A (en) | 1989-12-19 | 1991-03-05 | Shawa Denko K.K. | Process for preparation of N-(α-alkoxyethyl)-carboxylic acid amide |
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| EP1159964B1 (en) | 2000-05-31 | 2009-10-28 | Pfizer Products Inc. | Use of growth hormone secretagogues for stimulating gastrointestinal motility |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| EP2389941A1 (en) * | 2004-08-18 | 2011-11-30 | Elixir Pharmaceuticals, Inc. | Growth-hormone secretagogues |
| JP2007063225A (ja) * | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| EA200970764A1 (ru) * | 2007-02-13 | 2010-04-30 | ХЕЛСИНН ТЕРАПЬЮТИКС (Ю. Эс.), ИНК. | Способ лечения расстройств, вызванных пролиферацией клеток, с применением стимуляторов секреции гормона роста |
| WO2008153027A1 (ja) * | 2007-06-11 | 2008-12-18 | Takeda Pharmaceutical Company Limited | ピロロキノリン誘導体およびその用途 |
| WO2009063993A1 (ja) * | 2007-11-15 | 2009-05-22 | Takeda Pharmaceutical Company Limited | 縮合ピリジン誘導体およびその用途 |
| WO2009139340A1 (ja) | 2008-05-12 | 2009-11-19 | 武田薬品工業株式会社 | ピラゾール化合物 |
| DK3524260T3 (da) | 2012-09-27 | 2023-10-09 | Elanco Animal Health Incorporated | Farmaceutiske sammensætninger til behandling af manglende appetit |
-
2011
- 2011-02-28 WO PCT/JP2011/054556 patent/WO2011105611A1/ja active Application Filing
- 2011-02-28 RU RU2012141061/04A patent/RU2012141061A/ru not_active Application Discontinuation
- 2011-02-28 CA CA2789750A patent/CA2789750C/en active Active
- 2011-02-28 JP JP2012501911A patent/JPWO2011105611A1/ja active Pending
- 2011-02-28 KR KR1020127024117A patent/KR20120131183A/ko not_active Application Discontinuation
- 2011-02-28 EP EP11747565.7A patent/EP2540721B1/en active Active
- 2011-02-28 CN CN201180009948.8A patent/CN102762564B/zh active Active
- 2011-02-28 ES ES11747565.7T patent/ES2615731T3/es active Active
- 2011-02-28 BR BR112012020377-0A patent/BR112012020377B1/pt active IP Right Grant
- 2011-02-28 US US13/580,479 patent/US10975070B2/en active Active
- 2011-02-28 MX MX2012009774A patent/MX341660B/es active IP Right Grant
-
2013
- 2013-01-31 HK HK13101402.5A patent/HK1174615A1/xx unknown
-
2021
- 2021-03-02 US US17/189,552 patent/US20210179613A1/en not_active Abandoned
-
2023
- 2023-12-18 FR FR23C1048C patent/FR23C1048I1/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102762564B (zh) | 2015-09-30 |
| FR23C1048I1 (fr) | 2024-01-19 |
| CA2789750A1 (en) | 2011-09-01 |
| US10975070B2 (en) | 2021-04-13 |
| MX341660B (es) | 2016-08-29 |
| MX2012009774A (es) | 2012-10-05 |
| JPWO2011105611A1 (ja) | 2013-06-20 |
| WO2011105611A1 (ja) | 2011-09-01 |
| BR112012020377A8 (pt) | 2018-01-02 |
| CN102762564A (zh) | 2012-10-31 |
| KR20120131183A (ko) | 2012-12-04 |
| US20210179613A1 (en) | 2021-06-17 |
| EP2540721A4 (en) | 2013-08-07 |
| BR112012020377A2 (pt) | 2016-05-10 |
| BR112012020377B1 (pt) | 2019-10-08 |
| EP2540721B1 (en) | 2016-12-14 |
| CA2789750C (en) | 2018-03-06 |
| EP2540721A1 (en) | 2013-01-02 |
| US20120322821A1 (en) | 2012-12-20 |
| ES2615731T3 (es) | 2017-06-08 |
| RU2012141061A (ru) | 2014-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1172006A1 (en) | Apparatus for hydrogenating biocompatible solution | |
| EP2680853A4 (en) | TREATMENT OF CANCER WITH DOPAMINE RECEPTOR ANTAGONISTS | |
| ZA201109334B (en) | Dosage forms of apixaban | |
| GB201106527D0 (en) | Therapeutic apparatus | |
| EP2603850A4 (en) | METHOD FOR AUTHENTICATING PHARMACEUTICAL FORMS | |
| HK1172602A1 (en) | Device for selectively hydrogenating biocompatible solution | |
| IL214919A0 (en) | Method for therapeutic use | |
| IL215865B (en) | Meloxicam formulation | |
| IL222328A (en) | Tissue microabulation system | |
| HK1174615A1 (en) | Ghrelin receptor agonist for treatment of dyscrasia | |
| GB2497035B (en) | Method of authentication | |
| IL224381B (en) | Application of b-functionalized dihydroxy-chlorins for pdt | |
| EP2566494A4 (en) | CXCR4 RECEPTOR COMPOUNDS | |
| EP2533780A4 (en) | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | |
| IL225395A0 (en) | A mutated androgen receptor antagonist | |
| GB2480740B (en) | Apparatus for protecting feet | |
| EP2539706A4 (en) | ARYLPIPERAZONE ANTAGONISTS OF OPIOID RECEPTORS | |
| ZA201202379B (en) | Antagonists of dsgs2 for treatment of cancer | |
| EP2594275A4 (en) | AGENT FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF DIABETES | |
| GB2481022B (en) | Anchor apparatus | |
| EP2647632A4 (en) | PROCESS FOR PREPARING A MESYLATE OF A-IMATINIB | |
| ZA201102919B (en) | Apparatus for placement of stent | |
| TWM401387U (en) | Multifunction structure of device for putting on shoes | |
| GB201016519D0 (en) | Apparatus for patient adjustment | |
| GB201018113D0 (en) | Use of an estrogen receptor ligang for treating disease |